A biomarker-based solution for the limited access to early diagnosis and assessment of autism.

This paper discusses new FDA-approved biomarker tests for diagnosing autism that could help address the severe shortage of autism specialists. Currently, families face long waits (often years) for diagnosis because there aren't enough qualified professionals. These new tests could help more children get diagnosed in their first three years of life, but this would require major changes to how diagnosis works and much more investment in training professionals to provide early intervention services.

This paper discusses the implementation of FDA-cleared biomarker-based diagnostic tools for autism as a solution to address critical shortages in diagnostic capacity. The authors highlight that current academic diagnostic models requiring 6-10 hours of specialized multidisciplinary teams are insufficient to meet community needs, resulting in diagnostic delays of several years. The biomarker-based procedures are presented as clinically validated alternatives that could maintain diagnostic quality while increasing access. However, successful implementation would require significant changes to current diagnostic care models and substantial investment in workforce training for both treatment providers and early educators to serve the anticipated doubling or tripling of early diagnoses.

If successfully implemented, biomarker-based diagnostics could transform autism diagnosis by reducing wait times and increasing early identification. However, this would require substantial healthcare system changes and workforce expansion to handle increased demand for early intervention services and therapeutic preschool programs.

This appears to be a commentary or opinion piece rather than an empirical study. No sample size, methodology, or original data are reported. The claims about biomarker effectiveness rely on previous validation studies not detailed in this abstract.

With the upsurge of community uptake in population-based early screening for autism, the main obstacle to increasing access to early treatment and intervention services is the extremely limited access to high quality diagnosis, specifically the shortage of expert clinicians. Diagnostic evaluation models deployed by academic centers of excellence, which typically require the investment of 6-10 hours by specialized multidisciplinary teams, is not a viable solution to the vast needs of communities, resulting in parents' "diagnostic odysseys" and delays, often of several years, for treatment, interventions and supports. Biomarker-based objective procedures for early diagnosis and assessment of autism are now available, clinically validated, and cleared for broad implementation by the US Food and Drug Administration (FDA). They are intended to increase access while maintaining high quality.

Such solutions, however, will require change in entrenched models of diagnostic care, and aggressive prioritization of the needs of the community at large. If these innovations are successful, the number of children diagnosed in the first three years of life will double or triple. This will, in turn, require much greater investments in resources for treatment, including massive workforce training of providers capable of delivering community-viable caregiver-mediated interventions, and of early educators capable of serving autistic children in therapeutic inclusive preschool settings.